cGAS (Peripheral Program)

Rare monogenic interferonopathies such as Lupus and Aicardi-Goutières syndrome are driven by the pathogenic accumulation of cytosolic dsDNA, which aberrantly activates the cGAS–STING pathway and leads to chronic type I IFN signaling. Together with our partners at IOCB, Prague, CD3 has developed a pipeline of advanced lead cGAS inhibitors which show strong suppression of systemic inflammation in vivo.